Schizophrenia
Xanomeline and Trospium: A Potential Fixed Drug Combination (FDC) for Schizophrenia—A Brief Review of Current Data
by Alok Singh, MD Dr. Singh is with All India Institute of Medical Sciences in Raipur, India. Funding: No funding was provided for this study. Disclosures: The author has no conflicts of interest relevant to the contents of this article. Innov Clin Neurosci. 2022;19(10–12):43–47. Abstract Xanomeline, a cholinergic agonist, was initially evaluated for the treatment […]
Impact of Lurasidone on Metabolic Parameters and Prolactin Levels Based on Differences of Psychiatric Diagnosis, Dosage, and Introducing Methods: An Observational Study
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital in Hiroshima, Japan. Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center in Yamaguchi, Japan. Funding: No funding was provided for this study. Disclosures: The authors have no […]
Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics
by JP Lindenmayer, MD; Beverly J. Insel, PhD; Anzalee Khan, PhD; McKenzie Osborne, BA; Abraham Goldring, MA; and Mary Seddo, BA Drs. Lindenmayer, Insel, and Khan, Ms. Osborne and Seddo, and Mr. Goldring are with Manhattan Psychiatric Center in New York City, New York. Drs. Lindenmayer and Khan and Mr. Goldring are with Nathan S. […]
Anatomical Association Between Schizophrenia and Cerebellum
by Rajashekar Reddy Yeruva, MD; Yafei Shang, MD; Ben Schoenbachler, MD; Sharon Nuss, MS; and Rif S El-Mallakh, MD Dr. Yeruva is with Baylor Scott and White Medical Center in Round Rock, Texas. Drs. Shang, Schoenbachler, El-Mallakh, and Sharon Nuss are with the University of Louisville School of Medicine in Louisville, Kentucky. FUNDING: No funding […]
Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments
by Philip D. Harvey, PhD; Michelle L. Miller, MS; Raeanne C. Moore, PhD; Colin A. Depp, PhD; Emma M. Parrish, BS; and Amy E. Pinkham, PhD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and Research Service at Bruce W. Carter VA Medical Center in Miami, Florida. Ms. […]
Role of Norepinephrine in Schizophrenia: An Old-fashioned but New Story from Emergency Medicine
Dear Editor: A number of hypotheses have been put forth regarding the etiology of schizophrenia, including dopamine hypothesis and glutamate hypothesis.1 However, a lesser known theory is that elevated norepinephrinergic signaling plays a causative role in schizophrenia.2 We treated a patient with septic shock schizophrenia who developed delusions and hallucinations following continuous norepinephrine infusion. This […]
The Role of Serum Lithium Concentration on Pill Burden in Psychiatric Populations
by Charisse Chehovich, PharmD; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Emily Leppien, PharmD, BCPS; and Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN Drs. Chehovich, Demler, and Trigoboff are affiliated with the Buffalo Psychiatric Center, New York State Office of Mental Health in Buffalo, New York and with the University at Buffalo School of Pharmacy […]
Scam Susceptibility in a Young, Schizoaffective Patient with Traumatic Brain Injury: A Case Report with a Review of Financial Exploitation Literature and Possible Therapeutic Interventions Gleaned from Traumatic Brain Injury Rehabilitation Research
by Paul C. McCormick, Jr., MD, and Jessica Simberlund, MD Drs. McCormick and Simberlund are with the Department of Psychiatry at Weill Cornell Medicine and the New York-Presbyterian Hospital in New York, New York. Dr. Simberlund is also with Weill Cornell Medical College in New York, New York. FUNDING: No funding was provided for this […]
Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo?
by David G. Daniel, MD; Alan Kott, MD; Jay Saoud, Phd; Remy Luthringer, PhD; Vadym Rud, MD, PhD; Andrii Skyrpnikov, MD, PhD; Rodica Stan, MD, PhD; Veselin Palazov, MD; Xingmei Wang, MS; and Michael Davidson, MD Dr. Daniel is with Signant Health in Mclean, Virginia. Dr. Kott is with Signant Health in Prague, the Czech […]
The Effects of Paliperidone Palmitate 1 Month on the Employment Status and Social Functioning of Patients with Schizophrenia
by Takashi Ohnishi, MD, PhD; Hisanori Kobayashi, PhD; Toshio Yamaoka; Tokiko Toma; Keiko Imai; Akihide Wakamatsu; and Kenichi Noguchi, PhD Drs. Ohnishi, Kobayashi, and Noguchi and Mr. Wakamatsu are with the Medical Affairs Division of Janssen Pharmaceutical K.K. in Tokyo, Japan. Mr. Yamaoka, Ms. Toma, and Ms. Imai are with the Drug Safety Surveillance Department, […]
